Mirati Therapeutics, Inc. (MRTX) Q2 2023 Earnings Conference Call August 8, 2023 4:30 PM ETCompany ParticipantsRyan Asay - Vice President-Corporate ...

Mirati Therapeutics, Inc.: Cracking KRAS Is Harder Than It Looks Apr. 21, 2020 2:10 PM ET Mirati Therapeutics, Inc. (MRTX) Stock MRTX 11 Comments 2 Likes Kerrisdale Capital Management ...

The analysts covering Mirati Therapeutics, Inc. (NASDAQ:MRTX) delivered a dose of negativity to shareholders today, by making a substantial revision to their statutory forecasts for next year ...

As you might know, Mirati Therapeutics, Inc. (NASDAQ:MRTX) just kicked off its latest full-year results with some very strong numbers. The overall earnings picture was okay, with revenues of US$3 ...

SAN DIEGO, Nov. 9, 2019 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical stage targeted oncology company, today announced the presentation of initial data from its ongoing ...

Mirati Therapeutics, Inc. (NASDAQ:MRTX) investors will be delighted, with the company turning in some strong numbers with its latest results. Overall results were decent, with revenues of US$11m ...

Shares of Mirati Therapeutics Inc. MRTX were down 4.7% premarket on Friday after the company said the European Medicines Agency had issued a negative opinion on a marketing application for ...

Less-than-stellar clinical data caused an analyst to downgrade the company's shares, sending investors to the exits. So what: Mirati Therapeutics provided updates on three of its ongoing clinical ...

INGELHEIM, Germany and SAN DIEGO, Sept. 17, 2020 /PRNewswire/ -- Boehringer Ingelheim and Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced a clinical collaboration to evaluate the ...

Mirati Therapeutics, Inc. is a biotechnology company whose mission is to discover, design and deliver breakthrough therapies to transform the lives of patients with cancer and their loved ones.

Adagrasib in combination with pembrolizumab demonstrates favorable tolerability and promising preliminary efficacy in patients with first-line advanced/metastatic NSCLC harboring a KRASG12C ...